SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " drug " 1,588 found 🔀 AI-powered Shuffle
Protein sciences in drug discovery 2026
ELRIG’s Protein Sciences in Drug Discovery 2026 meeting will be held at GSK Stevenage (UK) on November 10th-11th 2026.
The Math Singularity Is Here, and Science May Be Next
OpenAI has released an extraordinary body of mathematical work produced by an unreleased frontier model: 722 manuscripts spanning 372 research families across fields including number theory, complexity theory, and mathematical physics. Each result required, on average, the equivalent of roughly three hours of ChatGPT Pro reasoning. A New Era of Discovery We may be witnessing the beginnings of a “math singularity”: a point at which machine-generated discovery accelerates beyond humanity’s ability to independently reproduce, verify, or fully absorb it. If frontier models can generate hundreds of meaningful results in the time it takes a human researcher to investigate one, the constraint will no longer be producing new mathematics. It will be our capacity to validate, interpret, and integrate it. This does not make mathematicians obsolete. It changes their role. They may increasingly serve as guides, critics, and meaning-makers. Increasingly, they will decide which questions matter, determining which results can be trusted, and explaining why they are important. Mathematical insight may become abundant, while human judgment becomes more valuable than ever. Mathematics May Be Only the Beginning Every scientific discipline could eventually experience a similar acceleration. AI systems could generate and test hypotheses, connect findings across specialized fields, and explore possibilities at a scale no human research community could match. In medicine, imagine models identifying overlooked disease mechanisms, designing drugs and clinical trials, personalizing treatments, or discovering cures in months rather than decades. In materials science, AI could help create better batteries and cleaner industrial processes. In climate science, it could accelerate advances in energy, forecasting, and carbon removal. In biology, it could uncover relationships hidden across enormous genomic and molecular datasets. The result would not simply be faster research. It could expand the frontier of what is scientifically possible. The New Bottleneck Scientific discovery, however, is not the same as scientific progress. A medical breakthrough must still survive laboratory testing, clinical trials, regulatory scrutiny, manufacturing constraints, and real-world deployment. As machine-generated ideas multiply, the bottleneck may shift from producing breakthroughs to validating them safely and translating them into practice. We may soon have more hypotheses than laboratories can test, more drugs than clinical trials can evaluate, and more mathematical results than experts can review. That imbalance will require better systems for automated verification, reproducible research, prioritization, peer review, and collaboration between AI and domain experts. The importance of OpenAI’s work is not merely the number of manuscripts produced. It offers a glimpse of a world in which intelligence can explore thousands of intellectual paths in parallel. If ideas cease to be scarce, humanity’s defining challenge will be deciding which are true, which matter, and how to turn them into progress. The math singularity is not the end of human inquiry. It is the beginning of a new kind—one in which machines expand the frontier of knowledge and humans decide where it should lead. Subscribe Share Leave a comment
Trump administration paving way for temporary sale of some unapproved peptides
Food and Drug Administration scientists and some medical experts have raised alarms about increasing access to certain peptides.
GLP-1s: the science behind today’s weight-loss drugs
The medicines reshaping obesity treatment grew out of research into how the body handles a meal. Long before weekly weight-loss injections became familiar, scientists were studying signals that travel from the intestine to the pancreas, helping it release insulin when nutrients arrive.
Scientists win chemistry Nobel for discoveries about mirrored molecules that led to many drugs
Scientists Henri B. Kagan and Kenso Soai won the Nobel Prize in chemistry for untangling mysterious mirror images in molecules, a discovery that has been used to develop countless drugs.
See how redistricting will impact MS mental health, drug courts
Redrawn circuit and chancery court maps from 2025 will take effect in January 2027. See how judges say their courts will be impacted.
This is what the 2026 Nobel prize for chemistry is all about
The Nobel prize in chemistry 2026 has been awarded to two scientists, Henri B Kagan at Paris-Sud University in France and Kensō Soai at Tokyo University of Science in Japan. Their discoveries showed how chemical reactions can produce an overwhelming excess of one of two mirror image forms of a molecule. Science journalist Linda Geddes tells Madeleine Finlay how this has become an important tool in drug development, allowing a greater understanding of how medicines work in the body
People on weight-loss drugs report fingernails falling off as researchers uncover surprising link
Nail discoloration was reported by 46% of GLP-1 users versus 17% of non-users, while scalp inflammation accompanied hair loss in most medication users studied.
HOMETOWN HEALTH: How to keep the weight off after stopping GLP-1 drug
Many people rapidly regain weight after stopping GLP-1 weight loss drugs
Nobel Prize in chemistry goes to Kagan and Soai for 'mirror image' research
They developed methods to produce the desired mirror image in chemical reactions, which is crucial for drug design
Life sciences firm Danaher to launch AI-powered autonomous research lab in 2027
Oct 7 (Reuters) - Life sciences company Danaher said on Wednesday it plans to launch its first AI-powered autonomous research lab early next year to make drug discovery and development faster and more efficient.
Life sciences firm Danaher to launch AI-powered autonomous research lab in 2027
Life sciences company Danaher said on Wednesday it plans to launch its first AI-powered autonomous research lab early next year to make drug discovery and development faster and more efficient.
GLP-1 Drugs? Surgery? WHO Issues Guidelines For Obesity In Children
The World Health Organization (WHO) released its first-ever guidelines to address how clinicians should manage obesity in children and adolescents, which
Ingham County health officials urge overdose precautions after weekend spike
The Ingham County Health Department is urging residents to take precautions after a spike in drug overdoses over the weekend, including at least one suspected overdose death.
Ingham County health officials urge overdose precautions after weekend spike
The Ingham County Health Department is urging residents to take precautions after a spike in drug overdoses over the weekend, including at least one suspected overdose death.
Ingham County health officials urge overdose precautions after weekend spike
The Ingham County Health Department is urging residents to take precautions after a spike in drug overdoses over the weekend, including at least one suspected overdose death.
Ingham County health officials urge overdose precautions after weekend spike
The Ingham County Health Department is urging residents to take precautions after a spike in drug overdoses over the weekend, including at least one suspected overdose death.
Ingham County health officials urge overdose precautions after weekend spike
The Ingham County Health Department is urging residents to take precautions after a spike in drug overdoses over the weekend, including at least one suspected overdose death.
Ingham County health officials urge overdose precautions after weekend spike
The Ingham County Health Department is urging residents to take precautions after a spike in drug overdoses over the weekend, including at least one suspected overdose death.
Ingham County health officials urge overdose precautions after weekend spike
The Ingham County Health Department is urging residents to take precautions after a spike in drug overdoses over the weekend, including at least one suspected overdose death.
New global guidelines warn against obesity drugs for children under 10
Care should focus on healthy eating and exercise, not medicines such as weight-loss injections, says the World Health Organization
WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight
The World Health Organization on Wednesday recommended diet, exercise and counseling over popular weight-loss drugs in its first global guidelines addressing rising obesity among younger children.
Geoffrey Hinton suggests an FDA-style approval system for AI
Geoffrey Hinton said AI companies should have to convince a regulator their models are safe before releasing them, much like drugmakers.
Utah approves slew of health AI pilots for drug management, women’s health
The state has expanded its controversial healthcare AI program with three new pilots that could ultimately see the technology provide care plans and medications without human review.
Michael Douglas recalls conversations with Rob Reiner about having sons with ‘serious drug issues’
The “Basic Instinct” star’s son Cameron Douglas previously served a seven-year sentence in federal prison for drug possession.
Michael Douglas recalls conversations with Rob Reiner about having sons with ‘serious drug issues’
In his new memoir, Michael Douglas recalled conversations with Rob Reiner about having sons with ‘serious drug issues.’ Douglas’ son Cameron previously served a seven-year prison sentence for drug possession. Reiner’s son Nick wrote a semi-autobiographical film about his addiction.
Brazil: Lessons from a Disaster
By Antonio Martins (Outras Palavras) Defeats become deeper and more prolonged when we misunderstand what caused them, avoid correcting course, and embrace “solutions” that only compound our mistakes. Lula’s government and the Brazilian left suffered a disaster in Sunday’s election. Contrary to every poll, the president finished the first round 2.2 million votes behind Flávio Bolsonaro—and, more significantly, 3.4 million votes below his total four years ago, when the machinery of the state was working against him and in favor of his opponent. His vote share declined in 98 percent of Brazil’s municipalities. The PL, the main party of the far right, elected 121 deputies and 28 senators, becoming the largest caucus in both houses of Congress. The parties aligned with the Centrão—Brazil’s bloc of transactional center-right parties—were somewhat diminished, but will still hold roughly 250 seats in the Chamber of Deputies and 35 in the Senate. That will make it easier to assemble the majorities needed to amend the Constitution or impeach Supreme Federal Court justices. If elected, Flávio Bolsonaro could appoint four members of the Court, substantially altering its internal balance of power. What produced these results? How can the far right be prevented from consolidating them into a prolonged political hegemony? And what is the essential change of direction the left now needs? Explaining the Disaster Across the commercial media and the exuberant chaos of digital platforms, interpretations are multiplying. Some focus on specific episodes: Lula’s absence from the Globo debate, his very close relationship with Alexandre de Moraes, or his emphasis on issues supposedly remote from most people’s everyday concerns, such as rare earth minerals. Among the more systemic interpretations, three seem especially questionable. One argues that the principal defeat was not the left’s, since its congressional representation declined only slightly. The decisive movement captured at the ballot box, according to this view, was a shift within the right itself—from the more moderate and transactional forces of the Centrão toward the more ideological and radicalized forces of the PL and Novo. A second interpretation holds that the nature of electoral and political processes has changed. The material interests and aspirations of society, it argues, no longer play the central role they once did; they have given way to forms of subjective self-identification that the left has yet to understand. And a third concludes that, because of these two developments, we should expect a political winter: a prolonged period in which the far right and the broader right dominate Brazilian political life. There are important elements in all three interpretations. The problem lies in what they deny or leave out: Lula’s third government was a small-bore government. It offered the majorities that elected it neither a clearly better life nor reasons to believe again in politics and its power to transform society. These failures flowed from two fatal accommodations, which I will examine below. As a result, the government suffered a slow but steady erosion of support. And, as has happened in so many Western countries, it gave the far right the opportunity to present itself as anti-system and to benefit from popular frustration and distress. The interpretation that emphasizes the migration of votes from the center-right and traditional right toward the far right has been advanced, among others, by the courageous journalist Leonardo Sakamoto. In his UOL column on Monday, October 5, he highlights the miserable behavior of the traditional conservative parties. Over the past four years, they repeatedly joined forces with the “neo”-fascists, helping to “normalize” them—a criticism that could equally be directed at almost the entire corporate media. Believing they could use the far right as a stepping stone, they instead ended up partly devoured by it. This was especially true in the Senate, where the PL’s gain of 13 senators and Novo’s gain of two came at the expense of the PSD, which lost nine; the MDB, which lost two; the PSDB, which lost two; and the PP, which lost one. Sakamoto’s observation is accurate and necessary, but it leaves uncomfortable questions unanswered. Why did the erosion of the Centrão benefit the far right rather than, for example, producing growth for the left—as has happened so many times before, both in Brazil and elsewhere? The answer is not difficult. Throughout its four years in office, Lula’s third government was almost invariably associated with the Centrão. Here lies its first accommodation: accepting the limits imposed by conservative institutions; avoiding, as much as possible, any attempt to strain those limits through popular pressure; and believing only in the modest changes that could be squeezed through openings in Congress. The failure of the campaign to end the six-day workweek is emblematic. Lula could have electrified the presidential race by pairing it with a popular campaign for passage of the measure. Instead, he chose to place his hopes in the hands of Senate president Rodrigo Alcolumbre. He generated no mass mobilization, did not force his opponents onto an uncomfortable defensive, and won no victory. In September 2025, the government squandered the greatest of its many opportunities to shake up conservative power in Congress. Popular opposition to the so-called Shielding Amendment—which, if approved, would have restricted criminal proceedings against members of Congress—brought crowds into the streets, mobilized primarily by artists and social movements. This opened the possibility for a broader political education: a campaign that could begin exposing the limits and dysfunctions of Brazil’s political system while putting Bolsonaro’s movement on the defensive for its predictable support of political privilege. The amendment was defeated. But the executive branch then backed away from the fight. It remained associated with an institutional world widely seen as corrupt, elitist, and indifferent to ordinary people’s struggles. In doing so, it forfeited its credibility as a vehicle for the protest vote. On Sunday, it reaped the bitter fruits. Are We Doomed? Taking a different approach from Sakamoto, the philosopher Moysés Pinto Neto and other writers have drawn attention, in their first analyses of October 4, to the fragmentation of the public sphere produced by Big Tech platforms. Through their algorithms, these platforms present each person with a different view of social reality. As a consequence, it becomes much harder to identify common material problems and demands—for example, the fight for labor rights or for a properly funded public health system. Voters no longer embrace such demands, these authors argue, because they no longer see themselves as part of a collective. Instead, they tend to value the identities assigned to them by neoliberal subjectivity—the role of the entrepreneur, for example. On this interpretation, the left’s possible error lies in clinging to outdated illusions. Moysés’s warning is highly relevant and resonates with arguments such as Naomi Klein and Astra Taylor’s “Apocalyptic Fascism and the Billionaires’ Bet.” Unlike a century ago, the far right no longer promises a radiant future. It concentrates instead on resentment—especially that of young men. “They belong to a generation that fears it may never own a home, but compensates with the pleasure it gets from constantly provoking progressives online. Convinced their future has been stolen, they share memes romanticizing historical authoritarian regimes,” the authors write. But Moysés seems to confuse this danger with inevitability. He fails to see that the left’s answer cannot be adaptation. On the contrary, it must strengthen the possibility of politics as collective action. Nor does he recognize that precisely such a reversal is already becoming possible in some of the most promising mobilizations of the twenty-first century: the election, at the end of 2025, of the young Muslim Zohran Mamdani as mayor of New York, on a platform centered on the intensely material fight for an affordable city; the Left Party’s victory in Berlin two weeks ago, built around the demand to expropriate private real-estate corporations; and the very recent wave of demonstrations in Spain—including an occupation of Madrid’s Puerta del Sol—in which tens of thousands of young people mobilized by the Tenants’ Union have demanded limits on rents. By putting itself in the straitjacket of the “fiscal framework” in the first months of 2022, Lula’s third government adopted the second fatal accommodation of its term. Faced with conservative institutions and a country devastated by four years of Bolsonaro, increased public investment was the government’s remaining weapon for offering a more dignified life to the majority and forging an anti-conservative pact with them. The same state that disburses 1 trillion reais a year to enrich a small class of rentiers could instead spend money to extend the Family Health Strategy to every Brazilian, at a cost of 30 billion reais; provide full-day public schooling and childcare to all adolescents and children—and, especially, relief to their mothers; achieve universal sanitation while cleaning up polluted urban rivers; multiply metro systems; begin transforming the urban peripheries; and undertake many other urgently needed projects. In April 2023, an article in Outras Palavras warned that the fiscal framework could “shrink the Lula government and preserve the forces that condemn the country to inequality and regression.” A year later, another article showed that restraints on public spending were strangling policies vital to ordinary people and undermining the president’s popularity. In November 2024 came a reality check, in the form of the government’s humiliating defeat in the municipal elections. Even then, the fiscal lock was neither removed nor loosened. On the contrary: throughout the government’s four years, fiscal restraint remained central to its political narrative. The administration proudly proclaimed that it had “put the state’s accounts in order,” without grasping either how misleading that phrase was—given the payment of 1 trillion reais in interest—or how badly the message was hurting it politically. Lula finally woke up in September 2026. The increase in Bolsa Família benefits, after four years of being frozen; the announcement that anti-obesity drugs would be offered through Brazil’s public health system; and the ban on online betting showed that the state has the power to act decisively on behalf of the majority when those in government are willing to confront obstacles. The huge marches that closed the campaign in Fortaleza, Salvador, Rio de Janeiro, and São Paulo on the eve of October 4 showed how such initiatives can mobilize activists and the broader public. But it was too late—and too little to change the outcome of the first round. History has not ended The possibility of a turnaround in the three weeks leading up to November 25 cannot be ruled out. It will not be simple or easy. Lula must not only make up a deficit of 2.2 million votes; he must also offset the movement of voters who backed other right-wing candidates in the first round, most of whom are likely to move toward Flávio Bolsonaro. Pulling that off will require a broad, grassroots effort to win over voters, potentially reinforced by new initiatives from Lula. The coming hours and days will be decisive. If Bolsonaro’s movement also wins the presidency, the result will create a high-risk situation for Brazilian sovereignty and democracy. The enormous challenges posed by such an outcome would require the left to reexamine, in depth and with a genuine willingness to engage in self-criticism, its political projects—or its lack of them—and its practices. But would that mean we are condemned to the long winter of far-right hegemony that some analyses are beginning to forecast? It is far too early to say, suggests a recent text by Álvaro García Linera, the thinker who served as vice president of Bolivia under Evo Morales. His central hypothesis is that this political current will prove short-lived. At a moment when the entire world is once again talking about sovereignty and protecting national economies, the far right offers a stale, recolonizing neoliberalism. Its submission to the United States is as blatant and pathetic as Flávio and Eduardo Bolsonaro’s overtures to Donald Trump. Its project amounts to something like every man for himself: greater inequality, capitalism without limits, devastation, and supremacism. Will it work? In the United States, just two years into his second term, Trump himself is reaching record levels of unpopularity and may be on the verge of losing Republican control of both the House and Senate in November. Every new beginning is difficult. Whatever the outcome of the second round, the defeats of October 4 show how profoundly the Brazilian left will have to rethink and rebuild. But just as it would be foolish to underestimate the seriousness of its mistakes, it would be equally foolish to conclude that rebuilding a political project is no longer possible. History has not ended. The times are moving faster than ever. Originally published in Portuguese by Outras Palavras. English translation by Eric Blanc; I’ve added the subtitles. More We can’t stop the far right at home or abroad without a revitalized labor movement, which is yet another reason why you should become a sustaining supporter of the Emergency Workplace Organizing Committee (EWOC) — one of US labor’s pivotal bright spots. Relatedly, Jacobin published a short piece of mine reflecting on a decade of Bernie Sanders inspiring a whole new generation of young worker organizers.
McKesson, CD&R to take infusion therapy provider Option Care private in $5.8 billion deal
Drug distributor McKesson and private equity firm Clayton Dubilier & Rice on Tuesday agreed to take infusion therapy provider Option Care Health private in a deal worth about $5.8 billion including debt.
FT and Standard Chartered Book of the Year Award 2026
Contenders include titles on weight-loss drugs, AI weaponry and forecasting
FT and Standard Chartered Book of the Year Award 2026
Contenders include titles on weight-loss drugs, AI weaponry and forecasting
41st Great Sports Legends Dinner Supports Neuroscience Research at The Miami Project to Cure Paralysis
The 2026 Legends Dinner honored 11 athletes and announced a $1 million gift supporting drug discovery and The Miami Project’s research.
GTA 6 Could Finally Fix Gaming's Huge Drug Problem
Just because you can doesn’t mean you should
Did New Science Board Just Shift BioCryst's (BCRX) Investment Narrative?
BioCryst Pharmaceuticals recently formed a seven-member Scientific Advisory Board made up of experienced rare disease and drug development leaders to guide its research, clinical plans and regulatory approach. The depth of this board, spanning big pharma R&D, AI driven drug discovery and rare disease commercialization, directly targets BioCryst’s execution risk as it builds a broader pipeline beyond its current portfolio. We will now examine how BioCryst Pharmaceuticals’ investment narrative...
Health conference to cover GLP-1 drugs, hormone therapy, youth sports
The Area Health Education Center (AHEC) will host its 42nd Annual Update in Medicine Conference.
Doctors Should Keep an Eye on Your Mix of Medication. If They Don’t, You Should.
By Paula Span | KFF Health News Medications can snowball as we age. Pill organizers pile up. Prescriptions that are no longer necessary can mix with other drugs to create concerning side effects. “Once you get to six or seven prescription medications, you get a nearly 100% chance of some sort of ...
Utah plows ahead with more health AI pilots for prescriptions, women’s health
Utah plans to allow an AI product to evaluate patients and write new drug prescriptions without prior human review.
GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business
Medical device maker GE HealthCare said on Monday it would buy privately held Sofie Biosciences for $945 million in cash, in a move that strengthens its ability to manufacture and distribute PET imaging drugs.
Obesity Startup Ilant Health Bets Its Revenue On Better Patient Outcomes
Founder Elina Onitskansky's Ilant Health has raised over $22 million to pair weight loss drugs with dietitians, behavioral health and peer support.
The science behind targeted oral peptides
A new type of medication is tackling a problem that has long frustrated drug developers: how to deliver peptide therapies orally and hit their target more precisely.
Yale School of Medicine On the Science of Childhood Anxiety, Say, Anxiety Disorders Are the Most Common Mental Health Challenges In Youth
Credit: Matt Bradbury October 5, 2026 - By Isabella Backman - Anxiety disorders are the most common mental health challenges in youth. Left untreated, they can disrupt the lives of both children and their families. The good news is that with intervention, most children will overcome these conditions. Across Yale School of Medicine, scientists are working to understand anxiety at every level, from common anxious behaviors to molecular biomarkers in the brain. They are using their findings to develop and disseminate new evidence-based treatments for childhood anxiety. Today, the go-to treatment for childhood anxiety disorders is cognitive behavioral therapy (CBT). This is a form of psychotherapy that teaches children skills for confronting anxious thoughts and helps them practice managing situations that cause anxiety. While it is the gold-standard treatment backed by considerable scientific evidence, up to 50% of children will not see sufficient benefit from CBT alone. Wendy Silverman, PhD, Alfred A. Messer Professor in the Child Study Center, co-directs the Anxiety and Mood Disorders Program alongside Eli Lebowitz, PhD, associate professor in the Child Study Center. One of their main interests is learning how to improve outcomes beyond CBT. “We’re developing cutting-edge, research-based knowledge that can reduce the suffering that anxiety causes children and their families,” says Silverman. Changing parent behavior YSM experts are investigating how to improve CBT outcomes for children by involving the parents. Silverman’s research has uncovered two main components of parent intervention that improve childhood anxiety: not enabling children to completely avoid the things that make them anxious and taking steps to enhance their autonomy. Parents may unintentionally reinforce their child’s anxiety by allowing them to avoid what makes them anxious. They also may unintentionally limit the children’s sense of autonomy by being overly intrusive. “One of the things that we take pride in is that we’ve focused on trying to understand what parents need to do, and to test our ideas and see if changing the parents’ behaviors is enhancing the effects of CBT,” Silverman says. “Our findings thus far suggest that they do." As much as CBT can be helpful, it can also be challenging to get one’s child to do the necessary steps for CBT to work. This is one important reason why Lebowitz created a novel intervention program for parents named Supportive Parenting for Anxious Childhood Emotions (SPACE). Existing intervention programs often teach parents to act as therapists for their child, such as training them on how to practice breathing exercises. “It makes sense, but this doesn’t work very well in practice,” says Lebowitz. “And part of the reason, I think, is that it’s not easy to get your kid to do things, especially if they’re not excited about doing it.” SPACE is unique because it focuses entirely on parent involvement and changing parental behavior—children are not involved in the sessions. For example, parents learn how to use supportive messages that convey confidence that their child can tolerate and manage distress. “It might sound like a parent saying to a child, ‘I get that this is really hard for you, but I know that you can handle it,’” Lebowitz says. The program also works with parents to identify the ways in which they are accommodating anxious behaviors. “We’ll pick one thing that parents are doing that is an accommodation and help them make a detailed plan for how they’re going to change that,” Lebowitz explains. Treating Anxiety in Children and Adolescents Much of the existing research on SPACE has focused on parents of children under age 14. Ongoing studies are now exploring its use with parents of older teens. “Both anxiety and accommodation can interfere with normative developmental shifts during the teen years, including increased autonomy and individuation from parents,” says Rebecca Etkin, PhD, associate research scientist in the Child Study Center. “In this sense, SPACE may be particularly well-suited for anxious teens and their parents. We want to see whether it is effective during this distinct developmental window.” Unfortunately, many families in need of CBT face barriers, including limited availability of services and geographic constraints. One way to improve access is digital interventions. Silverman and her team are developing an evidence-based digitized intervention program for parents that they can access directly from their computer or smart phone. “The work we’re doing will be one of the very few parent interventions that is digitized and importantly tested for effectiveness,” she says. Creating interventions for anxiety-related challenges Silverman and Lebowitz recently received a generous gift to develop and test other interventions that help parents reduce other child anxiety-related behavioral and emotional difficulties, such as restrictive eating and unexplained somatic symptoms. One of these projects in particular focuses on understanding the risks of social media and its potential benefits, including offering a sense of connection. “A lot of research has focused on the idea that social media is harmful and the less of it the better,” says Lebowitz. “But we actually see is that this is not quite right—there are negatives, but there are also positives. So, we’re trying to get a little bit more nuanced of a picture.” The team is working with teens with social anxiety and their parents over an extended period to better understand their social media habits and how their anxiety levels affect engagement with different platforms. The teens will answer questions sent to an app on their phones about mood and social media usage in an effort to capture emotional responses as they unfold. “We hope to develop interventions that can help make the best of social media while protecting against the more problematic effects,” Lebowitz says. The brain’s role in anxiety Researchers are also testing therapies to address anxiety at the neurological and molecular levels. In collaboration with Dylan Gee, PhD, professor of psychology in Yale's Faculty of Arts and Sciences, and Hilary Blumberg, MD, John and Hope Furth Professor of Psychiatric Neuroscience at Yale School of Medicine, Lebowitz and Silverman are using brain imaging to identify changes in a child’s brain before and after parents enroll in SPACE. In one study, children viewed anxiety-inducing images while undergoing magnetic resonance imaging (MRI); the researchers conducted scans with and without the children’s parents nearby. Before SPACE, children’s brains were better able to activate the regulatory circuitry needed to turn off an anxious response when their parents were nearby. But after SPACE, children could activate this circuitry even without the parent around. “As parents work on gradually reducing some of their accommodations, you can see a child get better at regulating their own fear system in the brain,” Lebowitz says. “It’s remarkable.” Research into the molecular underpinnings of anxiety can also inform new childhood anxiety treatments. In a recent study, Lebowitz, Silverman, and Flora Vaccarino, MD, Harris Professor in the Child Study Center, discovered that a protein known as fibroblast growth factor 2 (FGF2) could be protective from the toxic effects of stress. FGF2 levels in children and their parents were linked to the children’s risk of developing anxiety and depression, the study showed. The findings could help explain why some children who are exposed to early life trauma such as poverty or abuse are more prone to developing mental health disorders. And FGF2 could be a target for treatment. “This is very novel because it starts to give a clue to what is the molecular chain that connects those lived experiences to the actual psychological outcomes,” Lebowitz says. New ways to study and treat childhood anxiety Michael Crowley, PhD, associate professor in the Child Study Center, collaborates with Silverman and Lebowitz to study the role that attention plays in development and maintenance of childhood anxiety. There is a large body of research that shows that anxious children, like anxious adults, are prone to focus on threatening stimuli such as angry faces compared with neutral faces. This has led to innovative interventions that involve attention retraining. The idea is that if experts train children to look away from threatening stimuli, it may reduce their anxiety—especially children with social anxiety who are most prone to attend to threats. The researchers have just completed a clinical trial for attention retraining with 10- to 14-year-olds with social anxiety disorders and are currently analyzing the findings. Besides this innovative attention retraining research, as Crowly notes, “I like to design tasks that are engaging to kids,” Crowley says. “My goal is to assess something without the kids knowing what we are assessing.” With this goal in mind, Crowley has created a virtual game, named Boom, to study threat processing in children with anxiety disorders. The game is similar to that of hot potato—the child and three digital players take turns virtually passing a ball to each other’s gloves. At some point, the ball turns into a bomb, and as the bomb lands in each player’s glove, the outline of the glove turns yellow. The goal is to avoid having the bomb go off in your glove. What isn’t obvious is that the game is designed to measure different types of threatening stimuli, both ambiguous and direct. In the game, the direct threat occurs as the bomb is traveling towards your glove. The ambiguous threat is the yellow outlined glove as it is unknown where the bomb will travel next. While children play the game, Crowley’s team measures their brain activity using electroencephalography (EEG). The researchers have discovered that in kids with anxiety, the brain reacts more strongly to ambiguous threats than it does in their peers, but less strongly to direct threats. They believe that the initial abnormally large brain response to not knowing where the bomb is going impairs the brain's ability to properly respond when the threat is actually traveling the child’s way. “The brains of children with anxiety are unable to differentiate between threats you need to do something about and those that are not your problem.” Michael Crowley, PhD, develops innovative games for studying anxiety in children and adolescents.Credit: Matt Bradbury Based on these insights, Crowley hopes to study whether interventions like attention training could restore appropriate threat processing. Crowley’s team is also working on a test called the Balloon Risk Avoidance Task, which evaluates risk-taking and avoidance behaviors. It features a digital balloon that is full of air and about to burst. Kids have six seconds to let air out of the balloon. The more air they let out, the less risk they face that the balloon will pop. But at the same time, the balloon becomes less valuable as it deflates. “The more air you keep in the balloon, the more points you get,” Crowley explains. So far, the researchers have found that when the balloons pop unexpectedly, teens with social anxiety show distinct brain responses. Studying these responses can help psychologists understand the underlying pathways driving the various manifestations of anxiety. The genetics of anxiety When Thomas Fernandez, MD, associate professor in the Child Study Center and of psychiatry, was still in training, there was a lot of excitement about understanding the genetics associated with autism spectrum disorder. Since then, scientists have identified around 250 genes associated with autism. The genetic contribution to anxiety disorders, on the other hand, has historically received less attention. Anxiety is less heritable than autism, but the genetic contribution for anxiety disorders that emerge in childhood may be higher than for anxiety disorders overall. While scientists estimate the heritability of anxiety disorders in general to be around 30% to 50%, some studies suggest higher heritability for certain childhood-onset anxiety presentations. “I saw firsthand how researchers in the field went about finding vulnerability genes for autism,” Fernandez says. “So, we’re using a very similar playbook for childhood anxiety.” “I saw firsthand how researchers in the field went about finding vulnerability genes for autism. So, we’re using a very similar playbook for childhood anxiety.” Thomas Fernandez, MD Associate Professor In the Child Study Center and in Psychiatry Now, Fernandez and Emily Olfson, MD, PhD, assistant professor in the Child Study Center, are studying children and their parents to identify genetic changes that are present in the child but not the parents, known as “de novo mutations.” “All of us have some de novo mutations—maybe about 50 to 100 sprinkled throughout the genome,” Olfson says. “But when they occur within the coding regions of genes, they can be really disruptive.” Previous research shows that people with autism have higher rates of damaging de novo mutations than the general population. In 2022, Olfson, Lebowitz, Silverman, and Fernandez published a study on 68 children and their families that found that children with anxiety had similarly high levels of these mutations. Studying de novo mutations can help point the researchers to where they should be looking for genes associated with anxiety. “The end game is using the genes to steer us toward the right part of biology that we can then target to come up with better treatments,” Fernandez says. Building on those findings, the team is now studying more families to better understand how these de novo mutations, along with other genetic and environmental factors, shape pediatric anxiety disorders. They recently received a National Institutes of Health grant to enroll 750 new families over the next five years. Olfson is the principal investigator, with co-investigators Lebowitz, Fernandez, Silverman, and Shuangge Steven Ma, PhD, department chair and professor of biostatistics at Yale School of Public Health. Neurodevelopment, Risk Genes, and Mental Health Conditions - The Olfson Lab Joel Gelernter, MD, Foundations Fund Professor of Psychiatry, is interested in how different anxiety disorders differ genomically. “We are studying social phobia, panic disorder, and generalized anxiety disorder, working to understand why people differ in their risk to these specific anxiety disorders and evaluating various risk factors,” he says. Gelernter was recently involved in one of the largest studies to date of the genomics underlying anxiety disorder. The study included around 122,000 people with anxiety disorders and around 730,000 without. It found that some genetic differences associated with anxiety were linked to signaling that helps reduce overactivity in the nervous system. Many anxiety medications available today work by targeting this process. “It’s nice when the biology that you get out of a large genome-wide study ratifies things that we already know because that can help increase confidence in further findings from the study,” Gelernter says. Uncovering the neurobiology of psychiatric disorders John Krystal, MD, Robert L. McNeil, Jr. Professor of Translational Research and chair of the Department of Psychiatry, is interested in the neurobiology of psychiatric disorders, including post-traumatic stress disorder (PTSD), of which anxiety is a major symptom. In the late 1980s, Krystal’s team discovered that the drug yohimbine activated symptoms in patients with PTSD. “This was the first time we could link a specific biological mechanism to the symptoms of PTSD,” Krystal says. At the time, he adds, this finding was highly controversial. “A lot of people felt that PTSD was a purely psychological syndrome that didn’t have an underlying biology.” Since then, Krystal has dived deep into understanding the neurobiology of PTSD to learn how to better treat it. His team is evaluating the use of ketamine and psychedelics. These would be among the first treatments to be developed specifically for PTSD. They may also be applicable for other disorders including anxiety disorders, Krystal adds. An important gap in PTSD treatment is the absence of biological tests that inform how to best help patients manage their PTSD symptoms. A doctor doesn’t diagnose cancer based on how they feel. Rather, they use tests of the biology of the cancer to determine the best course of treatment. “And we can’t do that in any psychiatric disorder other than Alzheimer’s disease,” Krystal says. “But now we are building a foundation for this approach to the treatment of anxiety disorders for the first time.” Source: Yale School of Medicine
New kiosk is Erie County's latest effort to reduce drug overdoses, STDs
The kiosk was installed outside the Erie County Department of Health, 606 W. Second St., in mid-September and officially unveiled Oct. 1.
Doctors Should Keep an Eye on Your Mix of Medication. If They Don’t, You Should.
There’s a term for reducing unnecessary or harmful drugs: “deprescribing.” Especially as patients age, experts say, it’s important to regularly review the medications they’re taking.
At San Francisco General, researchers are learning how to control HIV without drugs
Doctors at San Francisco General Hospital's famed AIDS clinic have shown the immune system can be primed to keep the virus in check — a promising advance just as U.S. funding cuts threaten future research.
The Science Behind a Simple Headache Trick People Swear By
A viral trend promoting the placement of hair claw clips on eyebrows has captivated millions seeking fast headache relief without prescription drugs. If you have spent any time scrolling social media lately, you have probably spotted people clamping plastic claw clips directly onto their faces. It looks like an eccentric comedy sketch, but videos demonstrating this unusual trick have racked up more than 9 million views. Desperate headache sufferers are flooding comment sections, calling the clip
Inside the study for a remedy to fight Congo's deadliest Ebola outbreak
The drug is targeted at Bundibugyo virus, which is responsible for the fast-moving outbreak and is without an approved vaccine or treatment. The trial began in July and is one of several studies launched to find some protection and another way of at least slowing the outbreak.
Anthropic Is Aiming To Transform Healthcare—Here’s How
Anthropic is pushing Claude into prior authorization, medical records, drug discovery and global health. A physician explains what it means for doctors and patients.
GTA 6 rating pulled after revealing sex scenes and drug use
PEGI rating reveals GTA 6 details, including “frequent and prominent” drug use…
Weight Loss Drugs Give Restaurants a New Hurdle: Diners Who Eat Less
Fewer orders and higher costs are squeezing restaurants big and small as people on the weight-loss drugs eat and drink less when dining out.
Aetna 2027 Medicare plans offer reliable, affordable access to care & member support
Learn about Aetna's 2027 Medicare offerings, featuring affordable coverage, $0 preventive care services, prescription drug benefits, Healthy Home Visits, Special Needs Plans and enhanced member support.
Inside the study for a remedy to fight Congo’s deadliest Ebola outbreak
More than 250 participants have been enrolled in a trial for a drug that could stop them from contracting Ebola in Congo.
Breaking down Trump’s new ‘drug factories’ claim about Iranian nuclear sites
The president’s refusal to admit the likely gaffe follows a pattern of insisting he is always correct.
This week in health care policy: September 28 – October 2, 2026
Drug pricing CMS finalizes GLOBE pilot. On September 30, CMS finalized the Global Benchmark for Efficient Drug Pricing model, a program that ties Part B drug rebates to prices paid in 19 countries. It will cover physician-administered drugs in randomly selected communities throughout the US, representing about 25 percent of Part B beneficiaries. It runs […]
Drug Use, Nudity, and Sexual Fetishes All in GTA 6
Age rating descriptions share the details
GTA 6 Age Rating Confirms New Details on Sex, Drug Use, Decapitation, and More
GTA 6 has received a rating of PEGI 18, revealing mentions of "decapitation," the ability for players to snort cocaine at any time, "scenes of sexual fetishes," and much more.
Scientists Untangle the Biology of an ‘Undruggable’ Cancer Gene
Found in 70 percent of cancers, the gene is seen as a grand orchestrator but has been surprisingly difficult to stop.
A Heart Valve That Grows Up With The Patient Wins FDA Approval
By Ellyn Vohnoutka HealthDay ReporterFRIDAY, Oct. 2, 2026 (HealthDay News) — Children born with certain heart defects may face fewer open-heart surgeries, thanks to a new replacement valve that grows with them. The U.S. Food and Drug Administration (FDA) on Thursday approved the Autus ...
Royal College of Nursing cuts ties with Israeli drug company
Britain’s nursing union axes Teva UK as commercial partner over links to Israel’s military and corporate track record
Health Brief: Drugmakers unscathed by Trump’s drug price plan
Plus: Governors warn of a Medicaid work requirements crunch
50 children in our area hit by cars every year; toxic pond water in Centennial Park; ‘gas station heroin’; plus other stories with Vanderbilt Health sources
In a news report following a Murfreesboro child who was killed by an automobile, reporter Amber Jayanth from WSMV Channel 4 News cited statistics gathered at Monroe Carell Jr. Children’s Hospital at Vanderbilt about pediatric pedestrian injuries. Trauma registry data from Monroe Carell indicates that about 50 children per year on average are treated after being hit by a car. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: CNN (mRNA flu vaccine); ABC News and the American Journal of Managed Care (Pennsylvania measles outbreak); News Channel 5 (blue-green algae in the pond at Centennial Park, which can release toxins that make people and pets sick). WSMV Channel 4 News interviewed Saumya Aujla, MD, Assistant Professor of Clinical Physical Medicine and Rehabilitation, about the health risks of kratom, sometimes called “gas station heroin,” and why Tennessee banned the drug. WTVF News Channel 5 interviewed Brianna Smith, MD, Assistant Professor of Pediatrics, Hematology/Oncology at Monroe Carell Jr. Children’s Hospital at Vanderbilt for a piece on Childhood Cancer Awareness Month. Prevention interviewed Mitchell Gigandet, MD, Assistant Professor in the Neuro-Sleep Division, for a story about MDPI research on caffeine that used EEG imaging to see how the drug impacts sleep. It was found that caffeine may make sleep less restorative even when you fall asleep normally and stay in bed for eight hours. The Wall Street Journal reporter Laura Landro interviewed Joseph Schlesinger, MD, Professor of Anesthesiology Critical Care Medicine, for a story about ICU alarms keeping patients from getting sleep and creating alarm fatigue for nurses. Billboard reporter Melinda Newman interviewed country star Dasha about her upcoming vocal surgery at Vanderbilt Health. The story was picked up by numerous print and radio outlets including People.
Salt Lake business owner pleads guilty to laundering $17M in drug operation
A former Salt Lake County business owner pleaded guilty Wednesday to laundering more than $17 million in drug proceeds.
How Did Christa Pike Survive Two Lethal Injections of Pentobarbital?
A catheter carrying the lethal drug may not have delivered the doses to Ms. Pike’s bloodstream, experts said. The drug itself may have been degraded.
A Drug Extended Lifespan in 3 Very Different Species by More Than 25% Longer in a New Longevity Study
Directly activating a cellular energy sensor extended lifespan across three very different organisms.
HOMETOWN HEALTH: Doctors more cautious prescribing anxiety medication, studies show
Prescriptions for the anxiety drug benzodiazepine are declining in the United States.
Health, AI Innovations Prompt Longevity Concerns
TIAA study examines the retirement implications of tech including AI and weight-loss drugs, and the need for lifetime income
Scientists, Regulators and Industry Convene at PCPC’s 2026 Science Symposium
This annual event offers two days of presentations from experts in their fields, coupled with insight from US regulatory bodies like the Food & Drug Administration (FDA) and the Environmental Protection Agency (EPA).
Global Health & WASH: October 2026 Funding Opportunities (26 new opportunities)
41 opportunities on the Global Health & WASH page this cycle, 26 of them new. The health money on this page is mostly research money, and much of it is aimed at people early in their careers. Funder after funder, from the TANGO2 Research Foundation’s Research Pathways grants to the South African Medical Research Council’s Early Investigators Programme to the National Ataxia Foundation and Alex’s Lemonade Stand Foundation, is funding early-career investigators and the institutions that host them, with a clear tilt toward researchers based in or from the Global South, from AMBSO in Uganda to Kenya’s CONNECT-VAX network to Ersilia’s AI Incubator for African drug discovery. The money is organized by disease as much as by need: narrow foundations, the Parkinson’s Foundation, NTAP for neurofibromatosis, the RUNX1 Research Program for an inherited blood disorder, each run their own grant, so the question for an applicant is less which health problem you work on than which foundation owns your disease. The largest European cheques go to consortia only, with the European Innovation Council putting up to EUR €4 million behind a single healthy-ageing project and UNITE up to EUR €1 million behind each cross-border digital health team. Water sits apart, almost entirely in applied utility research: the Water Research Foundation’s cluster of USD $250,000 to $500,000 projects, each built around a utility problem from sewer laterals to reuse treatment. And the biggest single pot is public: HRSA is renewing community health center service areas with awards of up to USD $10 million each. This post is for paid subscribers. This helps support the time and effort it takes to curate and organize these opportunities. Subscribe To keep this accessible to everyone who needs it, we’re happy to offer pay what you can rates. You can find more details here. Open Opportunities 2027 Building the Field of Health Advocacy Grant, Georgia Health Initiative. *New!* *Closing soon!* Georgia Health Initiative, a nonprofit private foundation focused on health equity, is opening its 2027 Building the Field of Health Advocacy Grant to strengthen the organizations that push for healthier systems across the state. The Initiative treats advocacy as infrastructure, backing one-year projects that range from urgent responses to shifting federal policy to longer arc campaigns on housing, behavioral health, care access, and food security. It wants coalitions that elevate community voice, apply an equity lens, and arrive ready to deploy concrete strategies, and it deliberately seeks variety in issues, communities, and organizational size. The optional webinar and required lobbying training signal a funder investing in a durable field, not one grant cycle. The strongest fits are Georgia nonprofits and public agencies ready to turn advocacy readiness into systems change. Geographies: United States. Who can apply: Tax-exempt 501(c)(3) public charities, state or local government agencies, or coalitions/collaboratives using a 501(c)(3) fiscal sponsor, that work in Georgia on behalf of Georgians and align with the mission, vision, and values of Georgia Health Initiative. Only one application per organization, though an organization may be listed as a partner or subcontractor on multiple applications. Funding amount: Organizations can apply for up to USD $80,000 per project; the Initiative anticipates investing a total of USD $1.36 million. Targeted Sectors / SDGs: Governance, Policy & Advocacy · SDG3; SDG10. Deadline: October 2, 2026. Learn more and apply here. TDD Research Pathways Grant, TANGO2 Research Foundation. *New!* *Closing soon!* The TANGO2 Research Foundation, working with a founding gift from Tango2UK, is opening its TDD Research Pathways Grant to fund early-career investigators anywhere in the world who study TANGO2 Deficiency Disorder. The foundation is using this money to seed pilot work and to build a research community around a rare disorder that few labs currently study. It wants to back emerging scientists, clinicians, and trainees who will stay with this field, not one-off projects, which is why it requires a committed mentor and real institutional support and asks each applicant for a plan for future contributions. The design rewards promise and persistence over track record. The strongest fits are students, residents, postdoctoral fellows, and new investigators ready to commit to TANGO2 research. Geographies: Global. Who can apply: Early-career investigators worldwide, including undergraduate, graduate, and medical trainees, postdoctoral fellows, residents, and clinical or research fellows. Early-career investigators must hold a PhD, MD, or equivalent doctoral degree and be within 10 years of that degree or within 5 years of initiating rare disease research, engaged in postdoctoral research at an academic institution, teaching hospital, or nonprofit research institute. Currently enrolled trainees and transitional PhD candidates beginning a postdoctoral appointment at a nonprofit institution by July 1, 2026 are also eligible. All applicants must identify a qualified mentor with relevant TDD or rare disease research experience and demonstrate institutional support. Funding amount: Up to USD $15,000. Targeted Sectors / SDGs: Innovation, Science & Technology. Deadline: October 2, 2026. Learn more and apply here. Call for Expression of Interest (EOI): AMBSO Impact Research Initiative, Africa Medical and Behavioral Sciences Organization (AMBSO). *Closing soon!* The Africa Medical and Behavioral Sciences Organization is inviting expressions of interest for its Impact Research Initiative, which funds early-stage pilot studies and proof of concept work on priority health challenges. AMBSO is a Ugandan research organization backing bold ideas that can grow into larger studies, and its tracks span antimicrobial resistance, epidemic preparedness, artificial intelligence for diagnostics, HIV prevention, climate and health, cancer, maternal and child health, and non-communicable diseases. The small award size and direct-cost-only rule point to a funder that wants evidence rather than overhead, and that favors projects able to attract follow-on money or use AMBSO’s own research infrastructure. Eligibility runs worldwide, welcoming researchers and institutions inside and outside Africa. The strongest fits are researchers with a feasible pilot that generates policy-ready evidence. Geographies: Global. Who can apply: Open worldwide to researchers, academic institutions, and research organizations whose work aligns with generating high-impact health evidence. Independent researchers are eligible if affiliated with an academic or research institution. Doctoral students are encouraged to apply as part of a research team led by a faculty Principal Investigator. Community-based organizations and other eligible entities may apply. Projects may be implemented inside or outside Uganda. Funding amount: Up to USD $10,000 per project, with no minimum funding threshold. Targeted Sectors / SDGs: SDG3. Deadline: October 2, 2026. Learn more and apply here. Entrepreneurs for Resilience 2027 (E4R27), Swiss Re Foundation. *Closing soon!* Swiss Re Foundation is opening the tenth edition of Entrepreneurs for Resilience, which backs healthcare social enterprises expanding affordable, quality primary care for low-income communities across low- and middle-income countries. The Foundation is using catalytic, blended funding plus multi-year advisory to take risk out of scaling, helping proven models reach more people sustainably rather than stay stuck at pilot size. It looks to back brick-and-click enterprises that pair physical care with digital tools and build affordability through savings, payments, or microinsurance, ideally integrated with public health systems. Requiring earned revenue, real customer scale, and gender-inclusive teams signals that this is growth capital for commercially serious ventures, not seed money. The strongest fits are established, revenue-generating healthcare enterprises ready to scale access for underserved populations. Geographies: Global. Who can apply: For-profit and hybrid healthcare social enterprises serving low-income and underserved populations in low- and middle-income countries, using combined physical and digital (brick-and-click) healthcare delivery models. Applicants must demonstrate measurable social impact, generate at least 50% of income through earned revenue, have been established no later than December 2023, already serve at least 50,000 people with potential to scale, and have at least 30% low-income customers. Preference for gender-inclusive enterprises with at least one female founder or at least 30% women in management. Funding amount: Pilot funding of up to USD $45,000 for the 6-8 shortlisted social enterprises; up to USD $1 million in blended funding (up to USD $600,000 unconditional plus up to USD $400,000 conditional) shared among 3-4 finalists over a two-year implementation period; total programme funding approximately USD $1.3 million. Targeted Sectors / SDGs: Innovation, Science & Technology · SDG3; SDG5. Deadline: October 4, 2026. Learn more and apply here. Horizon HealthTech 2026, IIITD Innovation & Incubation Center. *Closing soon!* IIITD Innovation and Incubation Center is opening Horizon HealthTech 2026, a nine-month MedTech incubation cohort run under the aegis of BIRAC EDGE for founders building medical devices, diagnostics, surgical and interventional tools, or remote monitoring. The center is backing teams that already hold a validated proof of concept and want to reach a tested prototype, pairing each founder with a named expert and clinical validation through a hospital partner. What they seek to back is Indian health technology that can survive real clinical scrutiny and regulatory review, not slideware. The structure, with lab access, CDSCO guidance, IP support, and investor connects, signals a program built to make startups ready for follow-on capital. The strongest fits are early-stage MedTech teams with defensible IP and a working path from bench to bedside. Geographies: India. Who can apply: Early-stage teams/startups with a validated idea/proof of concept (TRL 3 onwards) working on medical devices, diagnostics, surgical/interventional technologies, or remote monitoring, holding IP or with potential to generate IP. Funding amount: No cash award amount is stated on the official program page. Benefits are in-kind: prototyping lab and equipment access, clinical/hospital validation (Max Healthcare), expert mentorship, CDSCO regulatory guidance, IP filing support, workspace, cloud credits and tools, and investor connects. Run under the aegis of BIRAC EDGE and builds a path to follow-on Government/VC/Angel funding. Targeted Sectors / SDGs: Innovation, Science & Technology · SDG3; SDG9. Deadline: October 5, 2026. Learn more and apply here. OpenAI AI and Teen Development Research Grant Program, OpenAI. *New!* *Closing soon!* OpenAI is opening its AI and Teen Development Research Grant Program to fund independent studies of how generative AI shapes the lives of young people ages 13 to 17. OpenAI wants a stronger evidence base on how teens actually use these tools and what that use does to their social and emotional development, so that product teams, policymakers, and regulators can act on findings rather than assumptions. It seeks work on emotion regulation, relationships, belonging, and the safeguards that keep teens safer, welcoming interdisciplinary teams and any methodology. That it will fund research whose conclusions may not favor AI providers, and prioritizes studies touching ChatGPT, signals a genuine appetite for credible outside scrutiny. The strongest fits are research groups grounded in adolescent development, well-being, and AI safety. Geographies: Global. Who can apply: Researchers aged 18 or older who are affiliated with a research institution or organization, and/or have significant experience relevant to child or adolescent development, well-being, human-computer interaction, AI impacts, or a closely related field. Multiple institutions may collaborate. OpenAI is seeking to fund research rather than for-profit initiatives and will not prioritize for-profit organizations. Funding amount: Individual research grants up to USD $1 million, totaling up to USD $5 million; maximum 10% of each grant for overhead or indirect costs. Targeted Sectors / SDGs: Social Inclusion & Community Wellbeing; Innovation, Science & Technology. Deadline: October 6, 2026. Learn more and apply here.
Amazon, GoodRx target U.S. prescription subscribers as health insurance coverage slips
Amazon.com, GoodRx and other companies offering online subscriptions that charge a flat fee for prescription drugs and other health services are reaping the benefits of Americans looking to combat rising costs and dwindling health insurance options.
September Monthly Review: Health MCP Guy?
For all the time I spend talking about APIs and data exchange, this newsletter has had embarrassingly little interoperability of its own. It’s old-school SaaS, baby - UI or bust. Not all of that is my fault! Substack, for all its popularity, is (as mentioned before) really frustrating as my system of record. The primary user it optimizes towards is the reader, whose attention feeds the app, the Notes feed, and the recommendation network that Substack is actually selling. Health API Guy is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Subscribe They’re falling into the same trap that Medium once sprinted into, albeit at a much more glacial speed. Younger generations may not remember (or never knew) it, but Medium once lured publications like The Ringer and Signal v. Noise onto its platform, only to lose them as it rebuilt itself around a paywall and an algorithmic feed. Substack’s original pitch circa 2020 was the antidote (you own your list), but every new feed feature chips away at it. I get it: writers are generic supply in the eyes of the Substack product team. Generic supply follows demand, so the consistent pressure on the PMs is to generate demand, which leads to every product cycle going toward discovery (Notes, recommendations, the app, live video). The end result lackluster author tools (laggy and broken analytics are truly crippling) all despite the premium price point. The archive is where it crosses from authorial gripes to actual reader impact, though. Across Substack and LinkedIn, I’ve published 1,218 posts and nearly 900,000 words since 2018. Substack’s native search can see only the 464 posts that live on Substack, and even there it’s woefully inadequate at surfacing relevant content (even for the guy who wrote it)! Readers have the same problem, writ large. Ask the Archive Fixing search (for both my readers and my own use) turned out to be extremely non-trivial, unfortunately: There’s no public API for readers to access content RSS exists for new content notification, but it only carries the 20 most recent posts and cuts paid ones off at the preview The only Substack MCP is an admin tool for analytics The export exists for authors, but it’s painfully awkward and slow. So I built something to work around that: the Health API Guy MCP. It’s a private MCP server holding the full text of everything I’ve written across Substack and LinkedIn. Add it to Claude or ChatGPT as a connector and you can ask things like: It pairs keyword search (for acronyms and case names, of which we have many) with semantic search. Every post is also labeled by topic, form, and court case, so you can pull a lawsuit’s (or multiple cases’) entire docket across Substack and LinkedIn in one query: Hail, Healthapiguyhydra This is also a bit of me eating my own cooking. I’ve spent the year arguing that headless healthcare is arriving and that developers want primitives over abstractions. Last week in Hail, Benihydra, I watched Salesforce plug its platform into Claude and bet that the records underneath outlive whatever interface sits on top: Salesforce must believe that the Hydra’s immortal head is the records, permissions, and business logic (in that they will survive whatever happens to the interface). It felt a bit hypocritical to keep my own archive behind a Substack search bar. The archive is the body. Substack is one head, and now whatever tool you might use is another. Will the EHRs follow my lead? Probably not imminently, but one can hope! Why Founding Members Only The MCP is available to Founding Member subscribers. A few reasons: It costs money and time to run. Hosting, the database, Clerk usage and AI compute for search and labeling are significant operational costs (that increase with usage). Substack gives me no way to automate access. There’s no API to check whether someone is a paid subscriber, so every user is manual operations for now. It’s a beta. We’ll need to improve things and parts will break. I’d rather they break for a small group of dedicated readers who will tell me about it. The Founding tier deserved a real benefit. Until now it was mostly a generous tip. Now it comes with something. If you’re already a Founding Member, reply to this email with the address you’d like provisioned. If you’re not and want in, upgrade here. Larger teams (such as companies) can get access too: group subscriptions at the Founding tier come with the group discount. The admin for the subscription can reply with the list of addresses to provision. Get 20% off a group subscription Pricing Founding membership is now a flat $200 a year, replacing the old suggested $150 that readers could adjust. Existing Founding Members will have access grandfathered in at their previous rate. Month in Review Articles Published Make Networks Dumb Again (Sep 11): AI is making old analog networks cheaper to use and flooding them with machine traffic in the process. A plea for agent-native rails with the intelligence at the endpoints, and for Washington to drag them to ubiquity. Interoperability, Unbuttoned (Sep 29): Interoperability is a series of workflows in a trenchcoat, and this post finally takes the trenchcoat off. A color-coded map shows which provider workflows went digital, which are fragmented, and which still run on fax. Video Content Antitrust’s System of Record Problem (Sep 3): The FTC’s investigation into Epic prompted a ninety-minute webinar, now posted with chapters and a smoothed transcript. We get into why market definition, missing B2B share data, and the SSNIP test leave antitrust poorly suited to systems of record, plus why information blocking may be doing more than any pending lawsuit. The Information Exchange: Cerner Milking Edition (Sep 18): This was so fucking fun. Ryan Tucker, Ryan Brickner, Brad Thorson, and I try an Around the Horn format, complete with points, penalties, and a mute button. We debate whether Oracle Health is dead, who would actually buy Cerner (IBM enters the chat), p(Doom), and why the front desk still hands you a clipboard. Regulatory Ask Not What Your Network Can Do (Sep 23): CDC’s RFI on public health data intermediaries lists use cases already served, unevenly, by eCR, lab reporting, IZ Gateway, and syndromic surveillance. The real opportunity sits in one question about AI: a network that can handle the next emergency without another interface project. Court cases Particle v. Epic: The Naughty Schoolteacher (Sep 4): After a summer-long vigil, the answer on Epic’s early summary judgment bid is two paragraphs and a remedial assignment. Particle advances to the next grade, and market definition gets another year of discovery. The Epic Discovery Files (Sep 8): Texas’s motions to compel arrive with a 251-page appendix of requests, objections, and meet-and-confer letters with Cravath. Inside: Epic using generative AI for document review, denied interoperability requests in scope, and Noerr-Pennington raised against lobbying discovery. Epic v. Health Gorilla: “Working as Designed” (Sep 9): Epic wants nothing to do with the data breach MDL, and explaining why puts fresh discovery on the public docket. The spiciest allegation: Health Gorilla told GuardDog to scrub its law firm business from its website instead of cutting off access. Veeva v. Epic: Legal Bypass Surgery (Sep 15): Veeva asks the Wisconsin Supreme Court to skip the Court of Appeals, while law professors and three policy groups line up as amici. Meanwhile, Epic’s lawyers apologize for another round of citation errors, including a quote that never existed. Texas v. Epic: Behind the Black Bars (Sep 17): The court portal served up Epic’s unredacted filings, revealing a $5 million document review budget and the AI workflow behind it. Also inside: the 200-plus company names Texas wants searched, and one very expensive Zoom invitation. OpenEvidence v. Doximity: Consequences Will Follow (Sep 25): OpenEvidence tells the court it will not comply with a discovery order, and its own lawyers at Quinn Emanuel say they won’t defend the choice. Add years of Slack reported unrecoverable, and Rule 37 sanctions come into view. Health Tech Keeps Choosing Violence (Sep 28): Doximity moves to end OpenEvidence’s case, Epic asks Texas to show its work, and a sleepy Audacious Inquiry patent fight sprouts antitrust and information blocking counterclaims. The main event is a long-sealed Cognizant v. Infosys ruling that hints where system of record antitrust claims can survive. EHRs One Verb for Oracle Health (Sep 14): Oracle’s earnings call quantifies every data center to the decimal point, while Oracle Health gets a single verb: “accelerate.” Panning the few healthcare mentions turns up an agentic care management system, a research-to-care ledger play, and the question of whether healthcare gets Larry’s patience. Epic’s Forretress Under Siege (Sep 30): Judy Faulkner tells a panel Epic paused hundreds of projects to harden its software and calls it a “shame,” while a spokesperson insists the roadmap hasn’t changed. Project Glasswing, a Pokémon-branded QAN sprint, and a trove of Jodel grievances reconcile the two Epics and preview the Jevons paradox coming for all software. Industry Analysis Scanning for a Network (Sep 1): Scan.com raises $220M to build the imaging network labs never got, speedrunning Zocdoc’s consumer-to-B2B pivot. Its wedge to network density may be the most American one available: personal injury litigation. The Front Desk Wants the Damn Whole Building (Sep 16): Hello Patient buys Converse Health, pushing its AI front desk into referrals, chart work, and prior auth. The copilot categories keep blurring, and your distribution partner is still your final boss. Cross-industry Comparisons A Different Patchwork Quilt (Sep 10): Healthcare loves to envy open banking, but the US version has no mandate, a toll booth at Chase, and data quality problems of its own. The grass isn’t greener; it’s another American patchwork quilt, and perhaps a worse one. Hail, Benihydra (Sep 21): Salesforce brings its platform into Claude, Slack, and its own agent, inviting the interfaces that might replace it. Cut off one head and more grow back, so long as the records underneath stay put. Living on A Trade Secret Prayer (Sep 22): Six credit unions are suing Fiserv, the Epic of core banking, by claiming their own member records as trade secrets. Banking has no Cures Act, so its lawyers reach for legal alchemy that healthcare has already tried. Other News None this month External Media Nabla Accelerate NYC: I kicked off fall conference season at Nabla’s Accelerate event in New York, where Delphine Groll opened by asking the room to picture the company it wants to become and the one it doesn’t. I liked her framework of bureaucracy, fear, and ego as the blockers. I also love vendor conferences/events in general - different vibe than industry biggies. Healthcare 101 with Nikhil Krishnan: I briefly guest lectured Out-Of-Pocket’s Healthcare 101 class. Appreciated Nikhil’s takeaways cover whether AI doctors can query HIEs, why healthcare’s data-liberation rules beat most industries’, and the hi-res graphic is in the comments. HCN: Epic Probed by the FTC: I joined the HCN guys to talk through the FTC’s investigation into Epic. Cedric’s new hairdo was an unexpected plot twist. The episode also covers MFN drug pricing, healthcare M&A and Eli Lilly’s acquisition streak. Fall Conferences: At eHealth Exchange’s Annual Meeting in Austin on Oct 27, I’ll moderate a panel on the tensions between AI, HIEs, and timely patient access with Jean Ross (Primary Record), Therasa Bell (Kno2), Byron Crowe (Doctronic), and Michael Marchant (Freenome). Here’s the rest of my schedule if you want to meet up: CommonWell (Redwood Shores, CA): Oct 13-14 Will be participating in a fun Jeopardy event Open@Epic (Madison, WI): Oct 20-23 Will be enjoying Verona, Willy Street, and other local adventures eHealth Exchange and Sequoia Project (Austin, TX): Oct 27-29 Yeehaw HLTH (Vegas): Nov 15-18 Groundhog Day, Venetian Edition RSNA (Chicago): Nov 30-Dec 2 See me at “Governing AI in Breast Imaging: What Health Systems Are Actually Doing” Digital Health Counsel 2026 AI Summit (Seattle): December 2-3 Will likely be speaking to a bunch of lawyers about information blocking Posts I Liked ChatGPT’s Epic integration: game changer or nothing burger?: Joshua Liu, MD offers five thoughts on OpenAI’s Epic launch, starting from the point that it rides the same open APIs available to anyone. He argues read-only access leaves ordering to Art and the ambient startups, and asks why HCA is piloting it alongside Commure. He’s sorta a must-follow at this point - consistently excellent, thought-provoking takes. Epic, Lilly, and the Discovery pass: Seth Chaney reads Epic’s first major Discovery deal (with Eli Lilly), as well as its revised developer terms on commercial displays, as the pipe finally opening between EHRs and pharma. Life sciences and health continue to collide. Scott Rossignol on EHR payer platforms and ePA fees: Scott argues the top ambulatory EHR vendors are turning the prior auth mandate into a per-member-per-year toll on payers, for an API whose operating cost has nothing to do with covered lives. His fix is two lines of regulatory text: put the CRD/DTR/PAS certification criteria in the Base EHR definition, and bring payer-facing ePA connectivity under § 170.404’s cost-based fee rules. It’s a good solution. Health API Guy is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Subscribe
AAPS PharmSci 360 Offers Fresh Insights for Industry Scientists
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.
Pete Davidson details his daily drug use before checking into rehab: ‘It got scary because I didn’t feel high’
Pete Davidson says he was doing acid, whippets, and ketamine while eating pills ‘every day’ at the height of his addiction, before checking into rehab after an emotional confrontation with his mother.
Illegal alien, former Utah business owner admits to laundering over $17M in drug proceeds
An illegal alien from Mexico and former Salt Lake County business owner admitted to her involvement in laundering more than $17 million in drug proceeds.Georgin
Rapid weight loss on popular drugs could ‘starve’ the brain, expert warns
Dr. Tommy Wood warns GLP-1 drugs like Ozempic and Wegovy can shrink brain tissue when caloric restriction cuts off vital energy the brain needs.
FDA seeks scientists and consumer representatives for advisory panels
The US Food and Drug Administration on Wednesday launched a nationwide effort to recruit scientists, medical experts and consumer representatives to its advisory committees, which advise the agency on drugs, vaccines and other regulated products.
Sugar Amplifies Damage Done to Gut Health by Antibiotics
/PRNewswire/ -- Eating sweets while taking antibiotics may worsen the harm done by the drugs to the normal community of bacteria in the gut, a new study found....
How recovering addicts may help feds take down Quality Behavioral Health
A lawyer said the government wants to shut down a much-needed drug rehab center, but pretends it wants to help patients who've been left high and dry.
What Does Anthropic’s Wet Lab Mean for Pharma?
Anthropic has established a wet lab in the San Francisco East Bay. In this article, experts explore what this means for scientific oversight, data ownership, and AI’s potential to transform drug discovery and rare disease research.
New Cancer Drugs Are Revolutionary. Why Don’t More Patients Get Them?
Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and sluggish change, are hindering access.
Drugs are widely used to sedate dementia patients. Her sons wanted to keep her off them
Potent sedating medications are often used on agitated people with dementia in long-term care facilities despite federal efforts to discourage them. A clash over whether to drug a Michigan woman illuminates the wrenching decisions families and guardians face.
‘Godzilla’ of weight-loss drugs could provide other important health benefits
Though not yet approved by any regulatory agency, Retatrutide could help improve blood sugar levels and reduce inflammation
Optimi Health Appoints Melanie Pump to Board of Directors
Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companiesVANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the “Company"), a commercial-stage manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced the appointment of Melanie Pump to its Board of Directors (the "
Amazon, GoodRx target US prescription subscribers as health insurance coverage slips
Amazon.com , GoodRx and other companies offering online subscriptions that charge a flat fee for prescription drugs and other health services are reaping the benefits of Americans looking to combat rising costs and dwindling health insurance options.
After Failed Execution, Health Workers Say State’s Rules Flout Medical Ethics
The death penalty is legal in 27 states, and lethal injection is the primary method. That means involving medical professionals to store, test, and inject the drugs. After a botched execution in Tennessee, doctors and nurses there say medical professionals need to be removed from the process completely.
Guest article: When nutrition becomes an evidence-based intervention, capital follows
Health and nutrition positioning alone buys nothing. Investors want evidence that products work and a moat competitors can’t easily replicate
Anthropic warns of ‘existential risks to humanity’ from AI; AstraZeneca makes $2bn cancer drug tie-up
Rolling coverage of the latest economic and financial news
DEA Highlights the Integral Role of Forensic Science in Addressing the Synthetic Drug Crisis
As synthetic drugs continue to evolve and threaten American lives, DEA chemists and forensic science professionals play an essential role in helping the U.S. Drug Enforcement Administration identify emerging threats, connect evidence to investigations, and provide timely information that can save lives. From analyzing suspected fentanyl and other novel synthetic drugs to examining fingerprints and…
New potent street drug prompts Hawaii health alert
Cychlorphine, a synthetic opioid up to 10 times stronger than fentanyl, has caused deaths across the U.S., prompting local officials to prepare for its arrival.
Veteran calls for changes after Green Bay VA stops offering mental health drug
Clinic no longer offers esketamine after certified doctor left
Veteran calls for changes after Green Bay VA stops offering mental health drug
Clinic no longer offers esketamine after certified doctor left
Could psychedelic therapy become NHS treatment for mental health?
Could hallucinogenic drugs become part of mainstream NHS care to treat depression?
Dyersburg gunfire investigation leads to drug arrest at South Main Avenue business
Dyersburg police arrested a local businessman on felony reckless endangerment and drug charges following an investigation into a Sept. 24 shooting involving two vehicles.
Kodiak Sciences Stock Surges 125% After Late-Stage Drug Trial Success
The trial tested two experimental eye drugs, Zenkuda and tabirafusp-ted, for treating wet age-related macular degeneration.
AbbVie partners with IPO-bound Iambic for AI-led drug discoveries
AbbVie is looking to a Nvidia-backed, AI-driven drug development company to accelerate its small molecule discovery.
The New Health Care Populism
Fear over rising costs is fueling bipartisan motivation to confront drug companies, insurers, and pharmacy benefit managers directly, with candidates on both sides racing to appear stronger on those areas than their opponents rather than litigating the Affordable Care Act. Republicans have been espe
Millions more people with overweight could benefit from GLP-1 drugs to protect heart health, study suggests
New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, makes a case for extending the indication for GLP-1 receptor ...
AEW's Brian Cage Defends PED Use
AEW star Brian Cage has acknowledged using performance-enhancing drugs, but maintains that it's quite possible to use them safely.
Jonathan Brill to Newsmax: AI Speeds Science, Drug Tests Take Time
Jonathan Brill to Newsmax: AI Speeds Science, Drug Tests Take Time
Radiation Exposure May Trigger a Key Feature of Alzheimer's in The Brain
A potential new drug target.
CDC vaccine policy recommendations grind to a halt under Health Secretary Kennedy - WSVN 7News | Miami News, Weather, Sports
NEW YORK (AP) — The Food and Drug Administration recently approved a new flu vaccine that tested well in older adults. But the federal agencyRead More
Blood test could gauge if a baby has a dangerous infection in 15 minutes
Feverish babies in hospital are often assumed to have a serious bacterial infection and are treated with antibiotics. But a test that gauges whether the infection is bacterial or viral, which tend to be milder, could prevent unnecessary drug use